Business
First commercial agreement for Ador
First commercial agreement for Ador.
About this update from Batm Advanced Communications Ltd.
[{"type":"text","content":"\n \nRNS Number : 9134Y BATM Advanced Communications Ld 07 January 2020 \n\nLEI: 213800FLQUB9J289RU66\n7 January 2020\n \nBATM Advanced Communications Limited\n(\"BATM\" or \"the Group\")\n \nFirst Commercial Agreement for Ador Diagnostics\nMolecular diagnostics subsidiary receives order for meningitis testing\n \nBATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, announces that Ador Diagnostics (\"Ador\"), the Group's subsidiary focused on the development and marketing of unique in-vitro molecular diagnostics solutions, has received its first commercial order from the leading Italian distributor of molecular biology and genomics products. Under the agreement, Ador will deliver the new NATlab reader and cartridges for the identification of meningitis in the second half of 2020.\n \nAdor's NATlab molecular biology solution provides rapid sample-to-answer diagnosis of bacterial, viral or fungal infections, within approximately 15-90 minutes, using DNA sampling. The unique system is modular, compact and mobile, and is designed to be used at the point-of-care as well as in hospital labs. The Group believes that NATlab will allow medical practitioners to provide far quicker and more efficient treatment.\n \nThis first commercial order for the new system follows extensive lab testing and the award of over 40 global patents, including in Europe and the US, with more pending. The first models of NATlab are expected to go into final trials in leading hospitals in the first half of this year, with the initial system having been already delivered this month. \n \nDr Zvi Marom, Chief Executive Officer of BATM, said: \"We are delighted that Ador has received the first commercial order for the NATlab system, which is an important milestone. Meningitis is a leading infectious cause of childhood death - and speed of identification and treatment is vital. We are proud that our rapid sample-to-answer solution will help medical practitioners to quickly and efficiently diagnose the specific infection and administer the required treatment.\n \n\"We believe NATlab will transform the infectious disease diagnostics market and we have already received extremely positive feedback and significant interest from several leading medical ins...